
Ask a doctor about a prescription for SAVENE 20 mg/ml POWDER FOR CONCENTRATE AND SOLVENT FOR PERFUSION SOLUTION
Package Leaflet: Information for the Patient
Savene 20 mg/ml powder and solvent for concentrate for solution for infusion
Dexrazoxane
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
5 Storage of Savene
Savene contains the active substance dexrazoxane, which acts as an antidote to certain anti-cancer medicines called anthracyclines.
Most anti-cancer medicines are given by injection into a vein. Sometimes an accident can happen and the medicine can leak out of the vein into the surrounding tissue or leak out of the vein into the surrounding tissue. This event is called extravasation. It is a serious complication because it can cause serious damage to the tissue.
Savene is used to treat anthracycline extravasation in adults.
It can reduce the amount of tissue damage caused by anthracycline extravasation.
Do not use Savene:
Warnings and precautions
Talk to your doctor or nurse before you start using Savene:
Children and adolescents
Savene must not be given to children under 18 years of age.
Using Savene with other medicines
Tell your doctor or nurse if you are using, have recently used or might use any other medicines.
In particular, tell your doctor or nurse if you are using or might use any of the following medicines:
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Savene must not be given if you are pregnant.
You must not breast-feed if you are being treated with Savene.
If you are sexually active, you are advised to use an effective method of contraception to prevent pregnancy during treatment and for 6 months after treatment, both if you are male or female (see section 2 “Do not use Savene”).
Information on the effect of Savene on fertility is limited. If you have any concerns about this, talk to your doctor.
Driving and using machines
Dizziness, fatigue and sudden fainting have been reported in a few patients treated with Savene. The treatment is considered to have a minor influence on the ability to drive and use machines.
Savene contains potassium and sodium
The Savene solvent contains 98 mg of potassium per 500 ml vial which may be harmful to people on a low potassium diet or who have kidney problems. If you are at risk of having high levels of potassium in your blood, your doctor will monitor this.
The Savene solvent also contains 1.61 g of sodium (the main component of cooking/table salt) per 500 ml vial. This is equivalent to 81% of the maximum recommended daily intake of sodium in the diet of an adult.
Savene will be given to you under the control of a doctor with experience in the use of cancer treatments.
Recommended dose
The dose will depend on your height, weight and kidney function. Your doctor will calculate your body surface area in square metres (m2) to determine the dose you should receive. The recommended dose in adults (with normal kidney function) is:
Day 1: 1,000 mg/m2
Day 2: 1,000 mg/m2
Day 3: 500 mg/m2
Your doctor may reduce your dose if you have kidney problems.
Savene will be given to you by infusion into one of your veins. The infusion will last 1-2 hours.
Frequency of administration
You will receive your infusion once a day for 3 consecutive days. The first infusion will be given as soon as possible and within the first 6 hours after anthracycline extravasation. The Savene infusion will be given at the same time each day of treatment.
Savene will not be used again in the next cycle of anthracycline treatment unless another extravasation occurs.
If you receive more Savene than you should
If you receive more Savene than you should, you will be closely monitored, with particular attention to your blood cells, possible gastrointestinal signs, skin reactions and hair loss.
If Savene comes into contact with the skin, the affected area should be rinsed immediately with plenty of water.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects can be serious and need immediate medical attention.
The following serious side effects have been reported in patients during treatment with Savene (frequency not known):
If you experience any of the above symptoms, seek medical attention immediately.
The following are other possible side effects:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Reporting of side effects
If you experience any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Monitoring System for Human Use: www.notificaRAM.es By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, the label on the powder vial and the label on the solvent vial after “EXP”. The expiry date refers to the last day of the month shown.
Store below 25°C.
Store the powder vials and solvent vials in the outer packaging to protect them from light.
What Savene contains
What Savene looks like and contents of the pack
The Savene pack consists of Savene powder for concentrate (white to off-white powder) and Savene solvent. An emergency pack contains 10 vials of Savene powder and 3 vials of Savene solvent supplied with 3 vial hangers.
The concentration of dexrazoxane after reconstitution with 25 ml of Savene solvent is 20 mg/ml. The concentrate is slightly yellow.
Marketing authorisation holder and manufacturer
Marketing authorisation holder
Clinigen Healthcare B.V.
Schiphol Boulevard 359
WTC Schiphol Airport, D Tower 11th floor
1118BJ Schiphol
Netherlands
Manufacturer
Cenexi-Laboratoires Thissen SA
Rue de la Papyrée 2-4-6
B-1420 Braine-L’Alleud
Belgium
Date of last revision of this leaflet: 07/2018
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
This information is intended only for healthcare professionals.
Preparation guide for use with Savene 20 mg/ml powder and solvent for concentrate for solution for infusion
____________________________________________________________________________
It is important that you read carefully the entire contents of this procedure before preparing Savene.
Savene is supplied as follows:
Savene powder must be reconstituted in 25 ml of Savene solvent to obtain a concentrate that must be further diluted in the remaining Savene solvent before administration.
Savene is an anti-cancer medicine, so the following normal procedures for handling and disposal of anti-cancer medicines should be followed:
3.1Reconstitution of Savene powder to prepare a concentrate
3.1.1 Using a syringe with a built-in needle, aseptically withdraw 25 ml from the Savene solvent vial.
3.1.2 Inject the entire contents of the syringe into the vial containing Savene powder.
3.1.3 Remove the syringe and needle and manually mix by repeatedly inverting until the powder is completely dissolved. Do not shake.
3.1.4 Allow the vial with the concentrate to stand for 5 minutes at room temperature and then check that the solution is homogeneous and clear. The concentrate is slightly yellow.
The concentrate contains 20 mg of dexrazoxane per ml and should be used immediately to further dilute. It does not contain antibacterial preservatives.
3.2Dilution of the concentrate
3.2.1 Up to four vials of Savene concentrate may be needed to obtain the required dose for the patient. Aseptically withdraw the appropriate volume, which contains 20 mg of dexrazoxane per ml, from the appropriate number of vials of concentrate, based on the dose required for the patient expressed in mg. Use a graduated syringe equipped with a needle.
3.2.2 Inject the reconstituted volume back into the opened Savene solvent vial (see point 3.1.5). The solution must not be mixed with any other medicine.
3.2.3 Mix the solution by carefully shaking the infusion vial.
3.2.4 Savene should be administered aseptically as an infusion over 1-2 hours at room temperature and under normal light conditions.
3.2.5 As with all parenteral products, Savene concentrate and the Savene infusion solution should be inspected visually for particulate matter or discolouration prior to administration. Solutions in which precipitation is observed should be discarded.
4.1 Before reconstitution and dilution:
4.2 After reconstitution and dilution:
All items used for preparation, administration or cleaning, including gloves, as well as any leftover liquid, should be disposed of in accordance with local regulations.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for SAVENE 20 mg/ml POWDER FOR CONCENTRATE AND SOLVENT FOR PERFUSION SOLUTION – subject to medical assessment and local rules.